DexCom has a lower P/E than the aggregate P/E of 56.86 of the Health Care Equipment & Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something important about this glucose monitoring specialist? DexCom shares last closed ...

If you are wondering whether DexCom's current share price really reflects what you are getting for your money, you are not alone. The stock last closed at US$73.67, with returns of 4.2% over 7 days, 9 ...

The average one-year price target for DexCom (XTRA:DC4) has been revised to 77,50 € / share. This is a decrease of 12.36% from the prior estimate of 88,43 € dated November 9, 2025. The price target is ...

Wall Street expects a year-over-year increase in earnings on higher revenues when DexCom (DXCM) reports results for the quarter ended December 2025. While this widely-known consensus outlook is ...

DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks ...

DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to Underweight from Equal Weight with a price target of $71, which was brought ...